

Size: 274mm x 218mm

NOTES

Read the instructions carefully before performing the test.

For in vitro diagnostic use only. NOT FOR MEDICINAL USE. For professional use.

The test is not intended for use in screening of asymptomatic individuals or for monitoring of success of therapy. Do not use beyond expiry date.

Do not intermix components of one kit with another.

Handle all specimens as potentially infectious.

Follow standard biosafety guidelines for handling and disposal of potentially infective material.

Clearing buffer contains Sodium Azide (0.1%), avoid skin contact with this reagent. Azide may react with lead and copper in the plumbing and form highly explosive metal oxides. Flush with large volumes of water to prevent azide build up in the plumbing. The test dipstick is intended for SINGLE USE ONLY.

Reduced light conditions increase risk of errors during testing and interpretation of test results. Make sure that the test performance and test interpretation is carried out in sufficient light conditions.

Contact with the contents of desiccant pouch containing, among other substances, cobalt chloride (CAS# 7646-79-9) should be kept to a minimum. Inhalation / swallowing may cause harm.

SPECIMEN COLLECTION AND PREPARATION

Fresh anti coagulated whole blood should be used as test sample and EDTA or Heparin or Oxalate can be used as suitable anticoagulant. The specimen should be collected in a clean glass or plastic container. If immediate testing is not possible then specimen may be stored at 2° To 8°C for upto 72 hours before testing. For long-term storage, freeze the specimen below -20°C. Repeated freezing and thawing of the specimen should be avoided (Maximum of 2 freeze/thaw cycles are allowed).

Thawed samples must be mixed gently prior to testing. Hemolysed, clotted or contaminated blood samples should not be used for performing the test. Fresh blood from finger prick / puncture may also be used as a test specimen.

TEST PROCEDURE AND INTERPRETATION OF RESULTS

- 1. Bring the paracheck Pf[®] kit components to room temperature before testing.
- 2. In case the pouch has been stored at 2°C To 8°C, allow atleast 30 minutes for the dipstick to come to room temperature.
- 3. Open the pouch and retrieve the dipstick (taking care not to touch the membrane area), sample applicator and desiccant. Check the colour of the desiccant. It should be blue. If it has turned colourless or pink discard the dipstick and use another dipstick. **Once opened, the dipstick must be used immediately.**
- 4. Label the dipstick with sample identity.
- 5. Tighten the vial cap of the clearing buffer provided with the kit in the clockwise direction to pierce the buffer bottle nozzle.
- Evenly mix the anti coagulated blood sample by gentle swirling. Dip the sample applicator into the sample. Ensuring that an applicator full of blood is retrieved, blot the blood so collected on to the sample pad just below the arrows on the dipstick (This delivers approximately 5µl of the whole blood specimen).

In case finger prick blood is being used, touch the sample applicator to the blood on the finger prick. Ensuring that an applicator full of blood is retrieved, immediately blot the specimen onto the sample pad just below the arrows on the dipstick (Care should be taken that the blood sample has not clotted and the transfer to the sample pad is immediate).

Alternatively, 5 µl of the anti coagulated or the finger prick specimen may be delivered to the sample pad just below the arrows using a micro pipette.

NOTE: Ensure that the blood from the sample applicator has been completely taken up by the sample pad.

- 7. Immediately dispense four drops of the clearing buffer into a clean 12 x 75 mm test tube by holding the plastic buffer bottle vertically.
- 8. Place the dipstick with the sample into the tube, with the arrows on the dipstick pointing downward and ensuring that the buffer level is below the blood sample for the entire duration of the test.
- 9. At the end of 20 minutes, read the results as follows:

NEGATIVE for *P. falciparum* malaria : A colored band appears on the dipstick.

		_	

POSITIVE for *P. falciparum* malaria : Two distinct colored bands appear on the dipstick.

\implies
\longrightarrow

INVALID: The test should be considered invalid if no colored band appears on the dipstick. The test should also be considered invalid if a colored band appears only at the test region and not at the control region. In such cases, repeat the test with a new dipstick, ensuring that the test procedure has been followed accurately.

QUALITY CONTROL RECOMMENDATIONS

To control proper test performance, it is recommended to include internal positive and negative control samples.

PERFORMANCE CHARACTERISTICS

Diagnostic Sensitivity And Specificity:

 In an internal study, a panel of 498 samples whose results were earlier confirmed with microscopy were tested with paracheck Pf[®]. The results obtained are as follows:

Sample type	Total no. of samples tested	paracheck Pf ®		Sensitivity*	Specificity*
	Totarno. or samples tested	Positive	Negative	%	%
Malaria negative	210	2	208	-	99.05%
P. vivax positive	114	0	114	-	100%
P. falciparum positive	154	153	1	99.35%	-
RF positive	20	0	20	-	100%

2. In an independent study, 192 whole blood samples of febrile patients whose results were confirmed by microscopy were tested with paracheck Pf[®]. The results obtained are as follows:

Sample type	Total no. of samples tested	paracheck Pf®		
Sample type	Total no. of samples tested	Positive	Negative	
Malaria negative	96	0	96	
P. vivax positive	40	1	39	
P. falciparum positive	50	49	1	
P. vivax & P. falciparum positive (mixed infection)	6	6	0	

paracheck Pf [®]was found to be 98.2% sensitive and 99.3% specific to *P. falciparum* malaria against microscopy. * Relative Sensitivity and Specificity at 95% confidence intervals.

Possible Interferences:

paracheck Pf[®] was tested using a variety of potentially interfering substances as given:

- a) Endogenous components: Substances such as bilirubin (direct, total), creatinine, triglycerides, uric acid, lipase proteins and others at high physiological levels.
- b) Exogenous components: substances such as anti-malarial drugs, antibiotics, anti-inflammatory drugs at high therapeutic concentrations.
- c) Pathogenic micro-organisms: micro-organisms such as HIV (1 and 2), HBV, HCV, M. tuberculosis, S. typhi and others. All samples tested generated negative results in paracheck Pf[®].

Precision:

Reproducibility and Repeatability studies (inter-assay and inter lot) were carried out using a number of malaria negative and Pv. positive samples; and of strong, low positive and limit of detection Pf. positive samples. **paracheck Pf** [®] generated results indicating 100% reproducibility and 100% repeatability.

From the above results and the results of in house data, **paracheck Pf** [®] is a highly sensitive and specific test for the diagnosis of *falciparum* malaria.

LIMITATIONS OF THE TEST

- 1. As with all diagnostic tests, the test result must always be correlated with clinical findings. Negative results must be confirmed by microscopic examination of thick smear and thin blood films. As is often done in serial microscopy testing, another sample may be collected and tested.
- 2. A positive result must be verified with a confirmation test.
- 3. Any modification to the above procedure and / or use of other reagents will invalidate the test procedure.
- 4. Interference due to presence of heterophile antibodies in patient's sample can lead to erroneous analyte detection in immunoassay, has been reported in various studies.paracheck Pf[®] uses HETEROPHILIC BLOCKING REAGENT (HBR) to inhibit majority of this interference.
- 5. In *P. falciparum* malaria infection, HRP-2 is not secreted in gametogony stage. Hence, in "Carriers", the HRP-2 band may be absent.
- 6. Since the Pf. HRP-2 persists for upto a fortnight even after successful therapy, a positive test result does not indicate a failed therapeutic response.
- 7. In case the test needs to be used to monitor success of therapy, testing is advised only from 15 days after the completion of therapy.
- 8. Do not interpret the test results beyond 30 minutes.



This product is designed to perform as described on the label and package insert. The manufacturer disclaims any implied warranty of use and sale for any other purpose

BIBLIOGRAPHY

- 1. Howard, R. J., et al., 1986 : Secretion of Malarial Histidine-Rich Protein (Pf. HRP II) from Plasmodium falciparum-infected Froward, N. S., et al., 1960. Occupient of Malanan Installine-recent Potent (1971) Information and Information an
- HRP-III in Malaria Parasites of Diverse Origin. Parasitol., 95, 209-227.
- 3. Parra, M.E., et al., 1991 : Identification of Plasmodium falciparum Histidine-Rich Protein 2 in the Plasma of Humans with Malaria, J. Clin. Microbiol., 29, 1629-1634.
- Rodriguez-Del Valle, M., et al., 1991 : Detection of Antigens and Antibodies in the Urine of Humans with *Plasmodium falciparum* Malaria. J. Clin. Microbiol., 29, 1236-1242.
- 5. Data on file : Orchid Biomedical Systems.

SYMBOL KEYS

0817/VER-02

X	Temperature Limitation	A**	Manufacturer	DIPSTICK	Dipstick	∑ ∑	Contains sufficient for <n> tests</n>
	Use by	[]	Consult Instructions for use	PIPETTE	Disposable Plastic Sample Applicator	2	Do not reuse
M	Date of Manufacture	REF	Catalogue Number	BUF	Clearing Buffer	11	This side up
LOT	Batch Number / Lot Number	IVD	In vitro Diagnostic Medical Device	EC REP	Authorised Representative in the European Community		



Orchid Biomedical Systems

A Division of Tulip Diagnostics (P) Ltd.

88/89, Phase II C, Verna Industrial Estate, Verna, Goa - 403 722, INDIA. Regd. Office: Gitanjali, Tulip Block, Dr. Antonio Do Rego Bagh, Alto Santacruz, Bambolim Complex P.O., Goa - 403 202, INDIA.

EC REP

CMC Medical Devices & Drugs S.L., Spain.